CN109180600A - A kind of thymol analog and its application - Google Patents
A kind of thymol analog and its application Download PDFInfo
- Publication number
- CN109180600A CN109180600A CN201811108568.XA CN201811108568A CN109180600A CN 109180600 A CN109180600 A CN 109180600A CN 201811108568 A CN201811108568 A CN 201811108568A CN 109180600 A CN109180600 A CN 109180600A
- Authority
- CN
- China
- Prior art keywords
- thymol
- analog
- application
- olsapozine
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
The invention discloses a kind of thymol analog and its application, shown in the thymol analog structure such as formula (I):
Description
Technical field
The present invention relates to field of medicaments, and in particular to a kind of thymol analog and its application.
Technical background
Inflammation is a clinical common pathologic process, can be born in the tissue and each organ at each position of body, such as hair
Capsulitis, tonsillitis, pneumonia, hepatitis, ephritis etc..Usually there is acute inflammation red, swollen, hot, pain, function the variation such as to hide, together
It is often accompanied by the general reactions such as fever, leukocytosis at any time.Clinically, the treatment of inflammation is with oral non-steroidal anti-inflammatory drugs
It is main.Olsapozine is one of clinically used non-steroidal anti-inflammatory drugs, to rheumatic arthritis, rheumatoid arthritis, Bones and joints
Inflammation, ankylosing spondylitis, neck shoulder wrist syndrome, scapulohumeral periarthritis, gout and wound and postoperative anti-inflammatory analgesic etc. have preferable effect
Fruit.But research is it has also been found that take for a long time, the adverse reactions such as patient Yi Fasheng digestive tract ulcer, serious liver and kidney dysfunction.Therefore,
Its structure is transformed, reducing or avoid its toxic side effect is the hot spot currently paid close attention to.
Thymol is also referred to as thymol, Thymol etc., can promote tra cheo-oesophageal voice, be conducive to tracheal mucus
Secretion, easily play phlegm-dispelling functions, then added with bactericidal effect, therefore can be used for treating tracheitis, pertussis etc..There is biology by two
Active group is effectively stitched together, and is the current important method for finding new medicine.Therefore, we are for the first time by olsapozine
Organically combine with thymol, to have the function that reduce toxic side effect, enhance its antiphlogistic effects.
Summary of the invention
The purpose of the present invention is to provide a kind of thymol analog and its applications in preparing anti-inflammatory drugs.
The structural formula of the thymol analog is as follows:
To achieve the goals above, The technical solution adopted by the invention is as follows:
The preparation of thymol analog provided by the invention: by 2.0mmol thymol, 2.0mmol under nitrogen protection
Olsapozine and 2.4mmol 1- ethyl-(3- dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate are added in 5mL methylene chloride
Dissolution, addition 0.2mmol dimethylamino naphthyridine are catalyst, react at room temperature 4h, with silica gel column purification up to the present invention after concentration
The thymol analog.
Pellet thymol analog application in preparing anti-inflammatory drugs.
The antiphlogistic effects of the thymol analog are 54.6%.
Specific embodiment
Purposes, technical schemes and advantages in order to better illustrate the present invention, below in conjunction with specific embodiment to this hair
It is bright to be illustrated.
Embodiment 1
The preparation of thymol analog of the present invention: under nitrogen protection that 2.0mmol thymol, 2.0mmol is difficult to understand
Sha Puqin and 2.4mmol 1- ethyl-(3- dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate is added molten in 5mL methylene chloride
Solution, addition 0.2mmol dimethylamino naphthyridine are catalyst, react at room temperature 4h, with silica gel column purification up to institute of the present invention after concentration
State thymol analog.
Embodiment 2
The present embodiment studies the anti-inflammatory effect of thymol analog by the mice auricle swelling model that phorbol exters induce.
Phorbol exters, olsapozine, thymol, the dissolution of thymol analog are stand-by in acetone.The female of 6 week old
ICR mouse 20 is only randomly divided into 5 groups, every group 4.Mouse right ear uses acetone, olsapozine, thymol and thymol respectively
Class Local treatment is stimulated with phorbol exters after 30min, and the mouse of unused phorbol exters stimulation is as blank control.To all after 6 hours
Mouse implements euthanasia, takes the auricle of mouse right ear 9mm diameter and weighing.And calculate inhibiting effect=[(only TPA)-(compound
+ TPA)]/[(only TPA)-(only acetone)] × 100%.
As the result is shown: inflammation, inhibiting rate 54.6%, hence it is evident that higher than olsapozine can be effectively suppressed in paeonol derivative
30.4% and thymol 10.8%.
Claims (3)
1. a kind of thymol analog, which is characterized in that the thymol analog is just like flowering structure formula:
2. a kind of application of thymol analog, which is characterized in that the application is the application prepared in anti-inflammatory drug.
3. the application of thymol analog according to claim 2, which is characterized in that the thymol analog is anti-inflammatory
Effect is 54.6%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811108568.XA CN109180600A (en) | 2018-09-21 | 2018-09-21 | A kind of thymol analog and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811108568.XA CN109180600A (en) | 2018-09-21 | 2018-09-21 | A kind of thymol analog and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109180600A true CN109180600A (en) | 2019-01-11 |
Family
ID=64909519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811108568.XA Pending CN109180600A (en) | 2018-09-21 | 2018-09-21 | A kind of thymol analog and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109180600A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2179032C1 (en) * | 2000-12-25 | 2002-02-10 | Закрытое акционерное общество "ИНТЕЛФАРМ" | Agent for chronic prostatitis healing |
| CN1352551A (en) * | 1999-05-27 | 2002-06-05 | 尤罗塞尔蒂克股份有限公司 | Preparations for the application of anti-inflammatory agents |
| CN102731301A (en) * | 2012-07-02 | 2012-10-17 | 栗进才 | Thymol ester derivatives, its preparation method and application thereof |
| US20170056347A1 (en) * | 2015-09-01 | 2017-03-02 | First Wave Biopharma | Methods and compositions for treating conditions associated with an abnormal inflammatory responses |
-
2018
- 2018-09-21 CN CN201811108568.XA patent/CN109180600A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1352551A (en) * | 1999-05-27 | 2002-06-05 | 尤罗塞尔蒂克股份有限公司 | Preparations for the application of anti-inflammatory agents |
| RU2179032C1 (en) * | 2000-12-25 | 2002-02-10 | Закрытое акционерное общество "ИНТЕЛФАРМ" | Agent for chronic prostatitis healing |
| CN102731301A (en) * | 2012-07-02 | 2012-10-17 | 栗进才 | Thymol ester derivatives, its preparation method and application thereof |
| US20170056347A1 (en) * | 2015-09-01 | 2017-03-02 | First Wave Biopharma | Methods and compositions for treating conditions associated with an abnormal inflammatory responses |
Non-Patent Citations (1)
| Title |
|---|
| 项光亚等: ""奥丙嗪衍生物的合成及其生物活性研究"", 《中国药物化学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004071400A3 (en) | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity | |
| CN102389423A (en) | Medicinal composition containing ibuprofen sodium salt | |
| DE60328722D1 (en) | METHOD FOR PRODUCING TANNATE TABLETS, CAPSULES OR OTHER SOLID DOSAGE FORMS | |
| EP2589382A1 (en) | Pharmaceutical composition comprising levocarnitine and dobesilate | |
| CN101810627B (en) | Compound sulfamonomethoxine/compound sulfamonomethoxine sodium injection and preparation method | |
| CN102406626B (en) | Pramipexole hydrochloride slow release tablet and preparation method thereof | |
| CN109180600A (en) | A kind of thymol analog and its application | |
| CN110755432A (en) | Application of nicotinamide in preparation of preparation for treating hand-foot skin reaction | |
| CN102631342A (en) | Application of epigallocatechin and pharmaceutical composition of epigallocatechin | |
| CN109260199A (en) | A kind of new application of paeonol derivative | |
| CN102319208A (en) | Suspension composition for treating oral mucositis caused by chemoradiotherapy | |
| WO2004058303A3 (en) | Compositions of benzoquinolizine carboxylic acid antibiotic drugs | |
| CN103520211B (en) | A kind of compound florfenicol injection and preparation method thereof and application | |
| CN100402039C (en) | Hair growth promoting liquid | |
| CN103550226B (en) | Compound sulfamonomethoxine sodium injection as well as preparation method thereof | |
| JP2015524460A5 (en) | ||
| CN110872280B (en) | Application of flavone C-glycoside monomeric compound | |
| CA2489705A1 (en) | Use of amide derivative of ge 2270 factor a3 for the treatment of acne | |
| JP2008285475A (en) | Anti-adenovirus agent containing loxoprofen | |
| CN106420601B (en) | Compound florfenicol injection for livestock and preparation method thereof | |
| WO2003090749A1 (en) | Use of berberine with high solubility in preparation of medicament | |
| CN101390849A (en) | Allitride composition and method thereof for preparing drop capable of treating nasal cavity microbial infection and use thereof | |
| CN1875924A (en) | An ibuprofen arginine compound medicament for children | |
| CN104274400A (en) | Oral suspension containing veterinary tolfenamic acid and preparation method of oral suspension | |
| CN103720647A (en) | Dexibuprofen injection composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190111 |
|
| WD01 | Invention patent application deemed withdrawn after publication |